Clinical Trial Update: Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update investigates adding glofitamab to alternating R-CHOP/R-DHAP chemotherapy in previously untreated mantle cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CISPLATIN (cisplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• CYTARABINE (CYTARABINE)
• DEXAMETHASONE (Dexamethasone)
• Doxorubicin (doxorubicin)
• Glofitamab (glofitamab)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING